The landscape of maternal health in India is a story of two realities. In one, we see the triumph of policy and public health initiatives that have slashed the Maternal Mortality Ratio (MMR) significantly over the last two decades. In the other, we see a stubborn, lethal persistence of hypertensive disorders that continue to claim the lives of thousands of women—lives that could have been saved with a simple, timely diagnosis.

To address the crisis of maternal death, we must move beyond generalities and look at the hard data. When we analyze the Sample Registration System (SRS) and National Family Health Survey (NFHS) data, a clear, urgent pattern emerges: Preeclampsia is not just a clinical complication; it is a systemic emergency that defines the gap between India’s health goals and its ground reality.

The Statistical Landscape: India’s MMR Journey

India has made commendable strides in reducing its Maternal Mortality Ratio. According to the Special Bulletin on Maternal Mortality released by the Registrar General of India, the MMR declined from 130 per 100,000 live births in 2014-2016 to 88 per 100,000 live births in 2021-2023. While this achievement met the National Health Policy target, it remains a far cry from the United Nations Sustainable Development Goal (SDG) target of less than 70 per 100,000.

However, the "88" figure is a national average that masks deep-seated inequalities. When we peel back the layers of these statistics, we find that Hypertensive Disorders of Pregnancy (HDP)—including Preeclampsia and Eclampsia—remain the second leading cause of maternal death in India, contributing to approximately 10% to 15% of all maternal fatalities. In some high-burden regions, this figure climbs even higher.

The Geography of Risk: State-Level Variations

The risk of dying from Preeclampsia in India is largely determined by the state in which a woman resides. The SRS data highlights a staggering disparity between "Empowered Action Group" (EAG) states and the rest of the country:

• Uttar Pradesh & Bihar: These states continue to struggle with some of the highest MMRs in the country (167 and 118, respectively). In these regions, the sheer volume of births combined with a fragile diagnostic net means that Preeclamptic seizures often occur at home or during transit, long before medical intervention is possible.
• Odisha & Assam: While Odisha has shown rapid improvement, Assam remains a critical concern with an MMR of 195. In these states, hilly terrains and flood-prone geographies make "time-to-care" the most significant risk factor for hypertensive emergencies.
• The Southern Contrast: In contrast, states like Kerala (19) and Tamil Nadu (54) have achieved figures comparable to middle-income or even high-income nations. The difference? Robust primary healthcare surveillance and near-universal screening for blood pressure and proteinuria during the first and second trimesters.

The Rural-Urban Divide: A Tale of Two Deliveries

The NFHS-5 (2019-21) data provides a granular look at the disparities in care quality between urban and rural India. While institutional births have risen to nearly 88.6% nationwide, the quality of the Antenatal Care (ANC) received remains inconsistent.

1. The Screening Gap

In urban centers, pregnant women are likely to undergo regular blood pressure monitoring and urine analysis. In rural pockets, however, the NFHS-5 reports that while a high percentage of women receive at least one ANC visit, the "full ANC" coverage (which includes 4+ visits, BP checks, and lab tests) drops significantly. In many rural districts of Bihar and Jharkhand, less than 30% of women receive the full recommended diagnostic protocol.

2. The Infrastructure Deficit

Rural health centers often lack the basic reagents required for protein detection. When a rural mother is part of the % of the population without access to diagnostic labs, her Preeclampsia remains "invisible." This leads to the most dangerous statistical trend: The Referral Trap. Data from the Lancet Global Health suggests that a significant portion of maternal deaths in India occur during "inter-facility transfer," where a woman is moved from a primary center to a tertiary center because the primary center lacked the tools to diagnose or stabilize her.

The Preventability Factor: Why Preeclampsia is the "Leaver"

The central angle of this crisis is simple yet devastating: A significant proportion of maternal deaths are preventable. Preeclampsia does not become fatal overnight. It follows a predictable, albeit silent, progression.

1. Stage 1: Sub-clinical placental dysfunction.
2. Stage 2: Early-onset proteinuria (protein in urine).
3. Stage 3: Hypertension and organ stress.
4. Stage 4: Eclampsia (seizures) and organ failure.

In India, the majority of deaths occur because the system only identifies the disease at Stage 4. By then, even the best tertiary care often fails. If we shift the "detection window" to Stage 2, the medical intervention required is often as simple as low-dose aspirin, magnesium sulfate, or a controlled delivery.

"We are not losing mothers to an incurable disease; we are losing them to a late diagnosis."

Bridging the Gap with Prantae: Early Screening as a High-Impact Lever

In the fight against maternal mortality, the most powerful tool is not a complex surgical intervention, but a timely data point. Clinical evidence suggests that the window for effectively managing Preeclampsia opens long before the first seizure occurs. When screening is integrated early into antenatal care (ANC), it acts as a "high-impact lever," shifting the healthcare paradigm from reactive emergency management to proactive clinical prevention.

The Necessity of Point-of-Care (PoC) Diagnostics

To close the quality-coverage gap identified in the NFHS-5 data, India requires a decentralized approach to diagnostics. Traditional "lab-centric" models are inherently biased toward urban centers, leaving rural mothers vulnerable to testing delays and referral fatigue. The solution lies in Point-of-Care (PoC) devices—portable, robust, and user-friendly tools that bring the laboratory to the patient’s bedside.

The integration of PoC technology offers three transformative advantages:

1. Immediate Actionability: Instead of waiting days for a lab report, a health worker can identify high-risk markers in minutes, allowing for immediate referral or "pre-loading" with life-saving magnesium sulfate.

2. Accuracy Over Subjectivity: While traditional dipsticks provide a vague color-coded guess of protein levels, modern PoC devices offer quantitative data. This precision is vital for tracking the "Albumin-to-Creatinine Ratio (ACR)," which is a far more reliable predictor of renal stress than blood pressure alone.

3. Data-Driven Surveillance: Digital PoC tools allow for the seamless logging of patient data. When screening results are digitized, district health officials can identify "hotspots" of hypertensive disorders in real-time, moving from reactive care to proactive public health management.

Redefining the Standard of Care

As we look to operationalize this high-impact screening, technology like Proflo-U® serves as a vital bridge. Designed specifically for the infrastructure gaps of the EAG states, it provides a no-lab, portable solution for measuring the Albumin-to-Creatinine Ratio (ACR). By placing such quantitative tools in the hands of primary health workers, we ensure that early screening isn't just a policy goal, but a practical reality. When early detection becomes the standard of care, we move closer to a future where the "numbers we can't ignore" finally begin to decline.

The Path Forward: From Data to Action

As we look toward the data that will emerge in NFHS-6, India has a choice. We can continue to track the deaths, or we can change the numbers by changing the tools.

To achieve the SDG target of MMR < 70, the strategy must evolve. We must move beyond "institutional delivery" as the only metric of success and focus on "Early Diagnostic Coverage." Recommendations for a Preeclampsia-Free India:

1. Universal Proteinuria Screening: Every ANC visit, especially in rural PHCs, must include a quantitative protein check.
2. Tech-Integration for ASHA Workers: Empowering frontline workers with portable tools like Proflo-U® to conduct screenings at the doorstep.
3. State-Specific Task Forces: Using SRS data to identify high-MMR districts and flooding them with point-of-care diagnostic infrastructure.

The numbers we see in the WHO and SRS reports are not just data points; they are a call to action. Preeclampsia is a leading contributor to maternal mortality, but it is also the most "detectable" threat. With the integration of innovative, portable solutions, we can ensure that the next set of statistics India publishes is defined not by the mothers we lost, but by the thousands of lives we had the foresight to save.

Key Data References:

• Office of the Registrar General, India (Sample Registration System Bulletin).
• International Institute for Population Sciences (NFHS-5 National Report).
• WHO Trends in Maternal Mortality 2000-2020.
• The Lancet Global Health: Maternal health in India – progress and challenges.